Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases - Summary - MDSpire
From the Journals

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...

  • By

  • Matthew Stenger

  • May 5, 2026

  • 3 min

Share

A multicenter phase II trial (PACHA-01) demonstrated that adjuvant hepatic infusion of oxaliplatin significantly enhances hepatic recurrence-free survival in patients after curative surgery for multiple colorectal liver metastases compared to intravenous delivery. The study involved 99 patients treated between June 2015 and December 2020, revealing a median hepatic recurrence-free survival of 25 months for the hepatic arterial infusion group versus 12 months for the IV group. These findings support the need for further phase III trials.

Original Source(s)

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

  • by Matthew Stenger

  • May 5, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min